---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-039935"
form_type: "8-K"
ticker: "ONCY"
cik: "0001129928"
company_name: "ONCOLYTICS BIOTECH INC"
filed_at: "2026-04-06T23:59:59+00:00"
generated_at: "2026-05-15T07:14:46.525547+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Oncolytics Biotech enters ATM agreement for up to $75M common stock offering

## Summary
- Agreement with Jefferies LLC allows sale of up to $75M in common stock at market prices.
- Proceeds to fund clinical development of pelareorep, R&D, operating costs, and general corporate purposes.
- Jefferies will receive a commission of 3.0% of gross proceeds; company also reimburses certain expenses.
- Shares sold under shelf registration effective April 3, 2026; prospectus supplement filed April 6, 2026.
- Company is not obligated to sell any shares; either party may terminate on ten trading days' notice.

## SEC filing metadata
- accession: 0001104659-26-039935
- form_type: 8-K
- ticker: ONCY
- cik: 0001129928
- company_name: ONCOLYTICS BIOTECH INC
- filed_at: 2026-04-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1129928/000110465926039935/0001104659-26-039935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1129928/000110465926039935/tm2610715d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-039935
- JSON: https://secwatch.observer/filing/0001104659-26-039935.json
- Plain text: https://secwatch.observer/filing/0001104659-26-039935.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.